Stock Price Movement and Market Context
On 27 Feb 2026, Remedium Lifecare Ltd’s share price declined sharply, closing at Rs.0.68, which represents a fall of 20.00% on the day. This marks the lowest price level the stock has seen in the past year and indeed its entire trading history. The stock has been on a consecutive four-day losing streak, cumulatively falling by 24.44% during this period. This decline notably outpaced the sector’s performance, with the stock underperforming the Trading & Distributors sector by 20.74% today.
The broader market also faced pressure, with the Sensex opening flat but subsequently falling sharply by 973.08 points, or 1.22%, to close at 81,247.40. The Sensex is trading below its 50-day moving average, although the 50-day average remains above the 200-day moving average, indicating some underlying market volatility.
Remedium Lifecare’s share price is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish trend.
Financial Performance and Key Metrics
The company’s financial indicators continue to reflect challenging conditions. Over the past year, Remedium Lifecare has delivered a negative return of 65.21%, significantly underperforming the Sensex, which posted a positive return of 8.91% over the same period. The stock’s 52-week high was Rs.1.95, highlighting the extent of the decline.
One of the critical concerns is the company’s ability to service its debt. The Debt to EBITDA ratio stands at -1.00 times, indicating a high leverage position relative to earnings before interest, taxes, depreciation, and amortisation. This ratio suggests limited capacity to meet debt obligations from operational earnings.
Remedium Lifecare has reported losses consistently, with a negative Return on Capital Employed (ROCE) reflecting the inefficiency in generating returns from capital invested. The latest half-year ROCE is reported at a low 0.08%, underscoring the subdued profitability.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Revenue and Profitability Trends
The company’s net sales have declined sharply by 65.79%, contributing to a series of negative quarterly results. Remedium Lifecare has reported losses for five consecutive quarters, with the latest six-month period showing a PAT (Profit After Tax) of Rs. -0.30 crore, which has deteriorated by 73.78%. The Profit Before Tax excluding other income (PBT less OI) for the quarter stands at Rs. -3.18 crore, a steep fall of 293.90%.
Operating profit growth has been stagnant, with a 0% annual growth rate over the last five years, indicating limited expansion or improvement in core business operations. The company’s EBITDA remains negative, which adds to the risk profile of the stock.
Long-Term and Short-Term Performance Comparison
Remedium Lifecare’s performance has been below par both in the near and long term. The stock has underperformed the BSE500 index over the last three years, one year, and three months. This consistent underperformance reflects ongoing challenges in business growth and profitability.
The company’s Mojo Score stands at 6.0, with a Mojo Grade of Strong Sell as of 9 April 2024, upgraded from a previous Sell rating. The Market Cap Grade is 4, indicating a relatively modest market capitalisation compared to peers.
Institutional Investor Activity
Despite the stock’s recent performance, institutional investors have increased their stake by 1.7% over the previous quarter, collectively holding 1.7% of the company’s shares. This increase in institutional participation suggests a degree of interest from investors with greater analytical resources, although it has not translated into a reversal of the stock’s downward trajectory.
Holding Remedium Lifecare Ltd from Trading & Distributors? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Financial and Market Indicators
Remedium Lifecare Ltd’s current stock price of Rs.0.68 represents a significant decline from its 52-week high of Rs.1.95. The stock’s performance over the past year has been negative, with a return of -65.21%, contrasting with the Sensex’s positive 8.91% return. The company’s financial health is marked by a high Debt to EBITDA ratio of -1.00 times, negative ROCE, and a series of quarterly losses.
Operating profit growth has been flat over the last five years, and net sales have contracted by nearly two-thirds. The company’s negative EBITDA and deteriorating profitability metrics contribute to its Strong Sell Mojo Grade. Institutional investors have marginally increased their holdings, but the stock remains below all major moving averages, reflecting ongoing market caution.
Market and Sector Comparison
Within the Trading & Distributors sector, Remedium Lifecare’s underperformance is pronounced. The stock’s 20.74% underperformance relative to its sector on the latest trading day highlights the divergence from sector trends. The broader market’s decline on the same day further compounds the stock’s challenges, although the Sensex’s technical indicators suggest mixed signals for the overall market.
Conclusion
Remedium Lifecare Ltd’s fall to a new 52-week low of Rs.0.68 underscores the persistent difficulties faced by the company in terms of financial performance and market valuation. The stock’s sustained decline, negative profitability metrics, and subdued growth indicators present a comprehensive picture of the current state of affairs. While institutional investors have shown some increased participation, the stock remains in a challenging position relative to its historical performance and sector peers.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
